Vincristine Sulfate
FDA-approved product (injectable, injection), marketed as Marqibo Kit, Oncovin, Vincasar Pfs and 3 more.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Vinca alkaloids and analogues
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli47.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae36.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Vincristine Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Dolutegravir SodiumExisting use: HIV infection, HIV-1 infection55.9% AI-predicted activityagainst E. coli50+ registered studies
- Desmopressin AcetateExisting use: Central diabetes insipidus, Diabetes insipidus, Enuresis and 5 more55.8% AI-predicted activityagainst E. coli50+ registered studies
- OxytocinExisting use: Hemorrhage, Uterine Inertia55.8% AI-predicted activityagainst E. coli50+ registered studies
- Cetrorelix AcetateExisting use: Ovulation Inhibition, Positive regulation of ovulation55.7% AI-predicted activityagainst E. coli50+ registered studies
- Setmelanotide AcetateExisting use: Obesity55.6% AI-predicted activityagainst E. coliNo documented evidence found
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more55.6% AI-predicted activityagainst E. coli50+ registered studies
- LurbinectedinExisting use: Cancer, Neoplasm, Small cell lung carcinoma55.4% AI-predicted activityagainst E. coli50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted55.4% AI-predicted activityagainst E. coli50+ registered studies
- Icatibant AcetateExisting use: Angioedema, Hereditary angioedema55.2% AI-predicted activityagainst E. coli33 registered studies
- Dihydroergotamine MesylateExisting use: Migraine disorder55.2% AI-predicted activityagainst E. coli21 registered studies
- Triptorelin PamoateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 3 more55.2% AI-predicted activityagainst E. coli50+ registered studies
- LypressinExisting use: Vasopressin and analogues55.1% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma
NCT00689845 · start 2007-06
Registered record
- Registry ID
- NCT00689845
- Conditions
- Lymphoma
- Interventions
- bleomycin sulfate; filgrastim; rituximab; cyclophosphamide; cytarabine; doxorubicin hydrochloride; etoposide phosphate; ifosfamide; methotrexate; prednisolone; prednisone; vincristine sulfate; vindesine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2007-06
- Completion
- Not recorded
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLymphomaInterventionbleomycin sulfate; filgrastim; rituximab; cyclophosphamide +9 morePhaseNot applicableRegistry statusUnknownA Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only
NCT00451178 · start 2007-05
Registered record
- Registry ID
- NCT00451178
- Conditions
- Lymphoma
- Interventions
- enzastaurin; rituximab; cyclophosphamide; doxorubicin; vincristine; prednisone
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2007-05
- Completion
- 2013-01
- Enrolment
- 101
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLymphomaInterventionenzastaurin; rituximab; cyclophosphamide; doxorubicin +2 morePhasePhase 2Registry statusCompletedTreating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease
NCT00107198 · start 2006-03-10
Registered record
- Registry ID
- NCT00107198
- Conditions
- Ann Arbor Stage I Childhood Hodgkin Lymphoma; Ann Arbor Stage II Childhood Hodgkin Lymphoma; Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma
- Interventions
- Conventional Surgery; Cyclophosphamide; Doxorubicin Hydrochloride; Prednisone; Radiation Therapy; Vincristine Sulfate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2006-03-10
- Completion
- 2026-03-31
- Enrolment
- 188
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnn Arbor Stage I Childhood Hodgkin Lymphoma; Ann Arbor Stage II Childhood Hodgkin Lymphoma; Childhood Nodular Lymphocyte Predominant B-Cell LymphomaInterventionConventional Surgery; Cyclophosphamide; Doxorubicin Hydrochloride; Prednisone +2 morePhasePhase 2Registry statusCompletedGEM05 for Patients With Multiple Myeloma Under 65 Years
NCT00461747 · start 2006-03
Registered record
- Registry ID
- NCT00461747
- Conditions
- Multiple Myeloma
- Interventions
- VBMCP/VBAD/Velcade; Thalidomide/Dexamethasone; Velcade/Thalidomide/Dexamethasone
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-03
- Completion
- 2008-12
- Enrolment
- 390
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMultiple MyelomaInterventionVBMCP/VBAD/Velcade; Thalidomide/Dexamethasone; Velcade/Thalidomide/DexamethasonePhasePhase 3Registry statusCompletedImatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00618501 · start 2005-10
Registered record
- Registry ID
- NCT00618501
- Conditions
- Leukemia
- Interventions
- cytarabine; daunorubicin hydrochloride; etoposide; imatinib mesylate; leucovorin calcium; methotrexate; prednisolone; therapeutic hydrocortisone; vincristine sulfate; allogeneic hematopoietic stem cell transplantation
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-10
- Completion
- 2009-01
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLeukemiaInterventioncytarabine; daunorubicin hydrochloride; etoposide; imatinib mesylate +6 morePhasePhase 2Registry statusCompletedStudy of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
NCT00290498 · start 2005-08-01
Registered record
- Registry ID
- NCT00290498
- Conditions
- Lymphoma
- Interventions
- Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Dexamethasone; Methotrexate; Cytarabine; Prednisone
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2005-08-01
- Completion
- 2017-08-11
- Enrolment
- 67
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLymphomaInterventionRituximab; Cyclophosphamide; Doxorubicin; Vincristine +4 morePhasePhase 2Registry statusCompletedStudy: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach
NCT00250718 · start 2004-10
Registered record
- Registry ID
- NCT00250718
- Conditions
- Non-Hodgkin's Lymphoma; Cancer
- Interventions
- Vincristine; VP-16; Rituximab; Dexamethasone; Levofloxacin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2004-10
- Completion
- 2014-05
- Enrolment
- 17
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-Hodgkin's Lymphoma; CancerInterventionVincristine; VP-16; Rituximab; Dexamethasone +1 morePhasePhase 2Registry statusTerminatedChemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia
NCT00458848 · start 2004-10
Registered record
- Registry ID
- NCT00458848
- Conditions
- Leukemia
- Interventions
- asparaginase; daunorubicin hydrochloride; etoposide; idarubicin; imatinib mesylate; mercaptopurine; methotrexate; methylprednisolone; mitoxantrone hydrochloride; prednisone; vincristine sulfate; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; radiation therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-10
- Completion
- 2014-03
- Enrolment
- 470
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLeukemiaInterventionasparaginase; daunorubicin hydrochloride; etoposide; idarubicin +11 morePhasePhase 2Registry statusCompletedCombination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma
NCT00054158 · start 2004-08
Registered record
- Registry ID
- NCT00054158
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- dexamethasone; doxorubicin hydrochloride; thalidomide; vincristine sulfate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-08
- Completion
- Not recorded
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMultiple Myeloma and Plasma Cell NeoplasmInterventiondexamethasone; doxorubicin hydrochloride; thalidomide; vincristine sulfatePhasePhase 2Registry statusCompletedCombination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma
NCT00110110 · start 2004-06
Registered record
- Registry ID
- NCT00110110
- Conditions
- Retinoblastoma
- Interventions
- filgrastim; Carboplatin; Cyclosporine; Etoposide; vincristine sulfate; cryosurgery; laser therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2004-06
- Completion
- 2024-12-31
- Enrolment
- 71
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRetinoblastomaInterventionfilgrastim; Carboplatin; Cyclosporine; Etoposide +3 morePhasePhase 2Registry statusUnknownCombination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma
NCT00416832 · start 2002-11
Registered record
- Registry ID
- NCT00416832
- Conditions
- Lymphoma
- Interventions
- cyclophosphamide; dacarbazine; doxorubicin hydrochloride; etoposide; prednisone; procarbazine hydrochloride; vincristine sulfate; radiation therapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-11
- Completion
- 2005-12
- Enrolment
- 648
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLymphomaInterventioncyclophosphamide; dacarbazine; doxorubicin hydrochloride; etoposide +4 morePhasePhase 2Registry statusCompletedStudy of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)
NCT00130195 · start 2002-09
Registered record
- Registry ID
- NCT00130195
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- imatinib; cyclophosphamide; daunorubicin; vincristine; prednisolone; methotrexate; cytarabine; dexamethasone
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-09
- Completion
- 2008-05
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Lymphoblastic LeukemiaInterventionimatinib; cyclophosphamide; daunorubicin; vincristine +4 morePhasePhase 2Registry statusCompletedRituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
NCT00669877 · start 2002-08
Registered record
- Registry ID
- NCT00669877
- Conditions
- Burkitt's Lymphoma; Burkitt'S-like Lymphoma
- Interventions
- Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Dexamethasone; G-CSF; Cytarabine; Methotrexate
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2002-08
- Completion
- 2015-10
- Enrolment
- 56
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBurkitt's Lymphoma; Burkitt'S-like LymphomaInterventionRituximab; Cyclophosphamide; Doxorubicin; Vincristine +4 morePhasePhase 2Registry statusCompletedSafety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
NCT00992992 · start 2001-06-28
Registered record
- Registry ID
- NCT00992992
- Conditions
- Lymphoma, Mantle-Cell
- Interventions
- Tositumomab and Iodine I 131 Tositumomab followed by CHOP
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2001-06-28
- Completion
- 2013-06-30
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLymphoma, Mantle-CellInterventionTositumomab and Iodine I 131 Tositumomab followed by CHOPPhasePhase 2Registry statusCompletedTITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma
NCT00002757 · start 2001-06
Registered record
- Registry ID
- NCT00002757
- Conditions
- Leukemia; Lymphoma
- Interventions
- filgrastim; cyclophosphamide; cytarabine; doxorubicin hydrochloride; etoposide; methotrexate; prednisolone; prednisone; therapeutic hydrocortisone; vincristine sulfate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2001-06
- Completion
- 2009-10
- Enrolment
- 1,148
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLeukemia; LymphomaInterventionfilgrastim; cyclophosphamide; cytarabine; doxorubicin hydrochloride +6 morePhasePhase 3Registry statusCompleted